Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intervention Strategies for Bipolar II Disorder With Rhythm Disturbance
NCT07654348Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jul 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
A Phase 2 trial of quetiapine (extended-release tablet, brand name: Bipresso) in Bipolar II disorder (BP-II), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
quetiapine (extended-release tablet, brand name: Bipresso)
03
Conditions
Bipolar II disorder (BP-II)
Beyond the preview
Go deeper on NCT07654348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07654348.